{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:08:40Z","timestamp":1794262120355,"version":"4.9.0"},"publisher-location":"New York, NY","reference-count":110,"publisher":"Springer US","isbn-type":[{"value":"9781071619230","type":"print"},{"value":"9781071619247","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1924-7_1","type":"book-chapter","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T22:02:37Z","timestamp":1646258557000},"page":"3-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions"],"prefix":"10.1007","author":[{"given":"Yee-Hung","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak P.","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"9","key":"1_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrcardio.2016.103","volume":"13","author":"JWE Moss","year":"2016","unstructured":"Moss JWE, Ramji DP (2016) Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol 13(9):513\u2013532. https:\/\/doi.org\/10.1038\/nrcardio.2016.103","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"1_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41569-019-0227-9","volume":"16","author":"GL Basatemur","year":"2019","unstructured":"Basatemur GL, J\u00f8rgensen HF, Clarke MCH, Bennett MR, Mallat Z (2019) Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol 16(12):727\u2013744. https:\/\/doi.org\/10.1038\/s41569-019-0227-9","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"1_CR3","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS et al (2021) Heart disease and stroke statistics - 2021 update. Circulation 143(8):e254\u2013e743","journal-title":"Circulation"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"104737","DOI":"10.1016\/j.phrs.2020.104737","volume":"155","author":"S Xu","year":"2020","unstructured":"Xu S (2020) Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction. Pharmacol Res 155:104737. https:\/\/doi.org\/10.1016\/j.phrs.2020.104737","journal-title":"Pharmacol Res"},{"issue":"9","key":"1_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1084\/jem.20060245","volume":"203","author":"J Jongstra-Bilen","year":"2006","unstructured":"Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI (2006) Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 203(9):2073\u20132083","journal-title":"J Exp Med"},{"issue":"10","key":"1_CR6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.7150\/ijbs.7502","volume":"9","author":"P Rajendran","year":"2013","unstructured":"Rajendran P, Rengarajan T, Thangavel J et al (2013) The vascular endothelium and human diseases. Int J Biol Sci 9(10):1057\u20131069","journal-title":"Int J Biol Sci"},{"issue":"2","key":"1_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/cphy.c180020","volume":"9","author":"Y Fang","year":"2019","unstructured":"Fang Y, Wu D, Birukov KG (2019) Mechanosensing and mechanoregulation of endothelial cell functions. Compr Physiol 9(2):873\u2013904","journal-title":"Compr Physiol"},{"issue":"4","key":"1_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.tips.2019.02.004","volume":"40","author":"N Niu","year":"2019","unstructured":"Niu N, Xu S, Xu Y et al (2019) Targeting mechanosensitive transcription factors in atherosclerosis. Trends Pharmacol Sci 40(4):253\u2013266","journal-title":"Trends Pharmacol Sci"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.autrev.2010.07.016","volume":"9","author":"S Sitia","year":"2010","unstructured":"Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, Tramontana S, Perticone F, Naccarato P, Camici P, Picano E, Cortigiani L, Bevilacqua M, Milazzo L, Cusi D, Barlassina C, Sarzi-Puttini P, Turiel M (2010) From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9:830. https:\/\/doi.org\/10.1016\/j.autrev.2010.07.016","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1124\/pr.118.017178","volume":"71","author":"D Wang","year":"2019","unstructured":"Wang D, Yang Y, Lei Y et al (2019) Targeting foam cell formation in atherosclerosis: therapeutic potential of natural products. Pharmacol Rev 71(4):596\u2013670","journal-title":"Pharmacol Rev"},{"issue":"7","key":"1_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbadis.2015.04.011","volume":"1852","author":"ML Buckley","year":"2015","unstructured":"Buckley ML, Ramji DP (2015) The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis. Biochim Biophys Acta 1852(7):1498\u20131510. https:\/\/doi.org\/10.1016\/j.bbadis.2015.04.011","journal-title":"Biochim Biophys Acta"},{"issue":"7757","key":"1_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1140-4","volume":"569","author":"L Huang","year":"2019","unstructured":"Huang L, Chambliss KL, Gao X, Yuhanna I, Behling-Kelly E, Bergaya S, Ahmed M, Michaely P, Luby-Phelps K, Darehshouri A, Xu L, Fisher EA, Ge WP, Mineo C, Shaul PW (2019) SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. Nature 569(7757):565\u2013569","journal-title":"Nature"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","volume":"116","author":"I Tabas","year":"2007","unstructured":"Tabas I, Williams KJ, Boren J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116:1832\u20131844","journal-title":"Circulation"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.plipres.2011.04.002","volume":"50","author":"JE McLaren","year":"2011","unstructured":"McLaren JE, Michael DR, Ashlin TG et al (2011) Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 50:331\u2013347","journal-title":"Prog Lipid Res"},{"issue":"8","key":"1_CR15","first-page":"11922","volume":"8","author":"J Zhang","year":"2015","unstructured":"Zhang J, Wang D, Shenghu H (2015) Roles of antibody against oxygenized low density lipoprotein in atherosclerosis: recent advances. Int J Clin Exp Med 8(8):11922\u201311929","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"1_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11596-019-2067-6","volume":"39","author":"Z-H Ruan","year":"2019","unstructured":"Ruan Z-H, Xu Z-X, Zhou X-Y, Zhang X, Shang L (2019) Implications of necroptosis for cardiovascular diseases. Curr Med Sci 39(4):513\u2013522","journal-title":"Curr Med Sci"},{"issue":"1","key":"1_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cyto.2013.05.016","volume":"64","author":"DR Michael","year":"2013","unstructured":"Michael DR, Ashlin TG, Davies CS et al (2013) Differential regulation of macropinocytosis in macrophages by cytokines: implications for foam cell formation and atherosclerosis. Cytokine 64(1):357\u2013361","journal-title":"Cytokine"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"24020","DOI":"10.1074\/jbc.R114.583658","volume":"29","author":"MC Phillips","year":"2014","unstructured":"Phillips MC (2014) Molecular mechanism of cellular cholesterol efflux. J Biol Chem 29:24020\u201324029","journal-title":"J Biol Chem"},{"issue":"1\u20133","key":"1_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S1388-1981(00)00154-2","volume":"1529","author":"BL Trigatti","year":"2000","unstructured":"Trigatti BL, Rigotti A, Braun A (2000) Cellular and physiological roles of SR-B1, a lipoprotein receptor which mediates selective lipid uptake. Biochim Biophys Acta 1529(1\u20133):276\u2013286","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00041433-200004000-00004","volume":"11","author":"BL Trigatti","year":"2000","unstructured":"Trigatti BL, Rigotti A, Krieger M (2000) The role of the high-density lipoprotein receptor SR-B1 in cholesterol metabolism. Curr Opin Lipidol 11(2):123\u2013131","journal-title":"Curr Opin Lipidol"},{"issue":"9A","key":"1_CR21","doi-asserted-by":"publisher","first-page":"13Q","DOI":"10.1016\/S0002-9149(98)00808-X","volume":"82","author":"PO Kwiterovich","year":"1998","unstructured":"Kwiterovich PO (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82(9A):13Q\u201321Q","journal-title":"Am J Cardiol"},{"issue":"12A","key":"1_CR22","doi-asserted-by":"publisher","first-page":"19L","DOI":"10.1016\/S0002-9149(00)01464-8","volume":"86","author":"WE Boden","year":"2000","unstructured":"Boden WE (2000) High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial. Am J Cardiol 86(12A):19L\u201322L","journal-title":"Am J Cardiol"},{"issue":"10","key":"1_CR23","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/archinte.159.10.1049","volume":"159","author":"CR Harper","year":"1999","unstructured":"Harper CR, Jacobson TA (1999) New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 159(10):1049\u20131057","journal-title":"Arch Intern Med"},{"issue":"7B","key":"1_CR24","first-page":"3J","volume":"88","author":"P Libby","year":"2001","unstructured":"Libby P (2001) What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 88(7B):3J","journal-title":"Am J Cardiol"},{"issue":"18","key":"1_CR25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18):1993\u20132000","journal-title":"JAMA"},{"issue":"3","key":"1_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08916934.2015.1027815","volume":"48","author":"T Shirai","year":"2015","unstructured":"Shirai T, Hilhorst M, Harrison DG et al (2015) Macrophages in vascular inflammation - from atherosclerosis to vasculitis. Autoimmunity 48(3):139\u2013151","journal-title":"Autoimmunity"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/19546","volume":"398","author":"RE Gerszten","year":"1999","unstructured":"Gerszten RE, Garcia-Zepeda EA, Lim YC et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718\u2013723","journal-title":"Nature"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0741-5214(03)00125-3","volume":"38","author":"JS Colonnello","year":"2003","unstructured":"Colonnello JS, Hance KA, Shames ML et al (2003) Transient exposure to elastase induces mouse aortic wall smooth muscle cell production of MCP-1 and RANTES during development of experimental aortic aneurysm. J Vasc Surg 38:138\u2013146","journal-title":"J Vasc Surg"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.atherosclerosis.2012.09.013","volume":"225","author":"JL Stoger","year":"2012","unstructured":"Stoger JL, Gijbels MJ, van der Velden S et al (2012) Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 225:461\u2013468","journal-title":"Atherosclerosis"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.imbio.2013.06.005","volume":"218","author":"IM Fenyo","year":"2013","unstructured":"Fenyo IM, Gafencu AV (2013) The involvement of the monocytes\/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 218:1376\u20131384","journal-title":"Immunobiology"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/ATVBAHA.108.180497","volume":"29","author":"A Mantovani","year":"2009","unstructured":"Mantovani A, Garlanda C, Locati M (2009) Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 29:1419\u20131423","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1111\/j.1582-4934.2009.00979.x","volume":"13","author":"M Simionescu","year":"2009","unstructured":"Simionescu M (2009) Cellular dysfunction in inflammatory-related vascular disorders\u2019 review series. The inflammatory process: a new dimension of a 19 century old story. J Cell Mol Med 13:4291\u20134292","journal-title":"J Cell Mol Med"},{"issue":"9","key":"1_CR33","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/nm.3258","volume":"19","author":"CS Robbins","year":"2013","unstructured":"Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weissleder R, Swirski FK (2013) Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 19(9):1166\u20131172","journal-title":"Nat Med"},{"issue":"5","key":"1_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.imbio.2012.02.015","volume":"217","author":"J Kzhyshkowska","year":"2012","unstructured":"Kzhyshkowska J, Neyen C, Gordon S (2012) Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 217(5):492\u2013502","journal-title":"Immunobiology"},{"issue":"6","key":"1_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41590-018-0113-3","volume":"19","author":"GJ Koelwyn","year":"2018","unstructured":"Koelwyn GJ, Corr EM, Erbay E, Moore KJ (2018) Regulation of macrophage immunometabolism in atherosclerosis. Nat Immunol 19(6):526\u2013537","journal-title":"Nat Immunol"},{"issue":"3","key":"1_CR36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","volume":"10","author":"RK Wadhera","year":"2016","unstructured":"Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol 10(3):472\u2013489. https:\/\/doi.org\/10.1016\/j.jacl.2015.11.010","journal-title":"J Clin Lipidol"},{"issue":"4","key":"1_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","volume":"104","author":"CK Glass","year":"2001","unstructured":"Glass CK, Witztum JL (2001) Atherosclerosis. The road ahead. Cell 104(4):503\u2013516","journal-title":"Cell"},{"issue":"7293","key":"1_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nu\u00f1ez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357\u20131361. https:\/\/doi.org\/10.1038\/nature08938","journal-title":"Nature"},{"issue":"11","key":"1_CR39","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4155\/fmc-2016-0072","volume":"8","author":"JWE Moss","year":"2016","unstructured":"Moss JWE, Ramji DP (2016) Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets. Future Med Chem 8(11):1317\u20131330","journal-title":"Future Med Chem"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/1358863X08094801","volume":"14","author":"E Adiguzel","year":"2009","unstructured":"Adiguzel E, Ahmad PJ, Franco C et al (2009) Collagens in the progression and complications of atherosclerosis. Vasc Med 14:73\u201389","journal-title":"Vasc Med"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/clp.11.73","volume":"7","author":"DR Michael","year":"2012","unstructured":"Michael DR, Ashlin TG, Buckley ML et al (2012) Macrophages, lipid metabolism and gene expression in atherogenesis: a therapeutic target of the future? J Clin Lipidol 7:37\u201348","journal-title":"J Clin Lipidol"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1161\/CIRCRESAHA.114.302355","volume":"114","author":"C Silvestre-Roig","year":"2014","unstructured":"Silvestre-Roig C, De Winther MP, Weber C et al (2014) Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 114:214\u2013226","journal-title":"Circ Res"},{"issue":"4","key":"1_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12471-017-0959-2","volume":"25","author":"SC Bergheanu","year":"2017","unstructured":"Bergheanu SC, Bodde MC, Jukema JW (2017) Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment. Neth Hear J 25(4):231\u2013242","journal-title":"Neth Hear J"},{"issue":"7","key":"1_CR44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4155\/fmc-2019-0301","volume":"12","author":"Y-H Chan","year":"2020","unstructured":"Chan Y-H, Ramji DP (2020) A perspective on targeting inflammation and cytokine actions in atherosclerosis. Future Med Chem 12(7):613\u2013626","journal-title":"Future Med Chem"},{"issue":"5","key":"1_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ki.2008.323","volume":"74","author":"B Haslinger-L\u00f6ffler","year":"2008","unstructured":"Haslinger-L\u00f6ffler B (2008) Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Kidney Int 74(5):553\u2013555. https:\/\/doi.org\/10.1038\/ki.2008.323","journal-title":"Kidney Int"},{"issue":"11","key":"1_CR46","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2174\/138161212799504803","volume":"18","author":"AS Antonopoulos","year":"2012","unstructured":"Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C (2012) Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 18(11):1519\u20131530. https:\/\/doi.org\/10.2174\/138161212799504803","journal-title":"Curr Pharm Des"},{"issue":"6","key":"1_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/bf02938395","volume":"9","author":"CY Campbell","year":"2007","unstructured":"Campbell CY, Rivera JJ, Blumenthal RS (2007) Residual risk in statin-treated patients: future therapeutic options. Curr Cardiol Rep 9(6):499\u2013505. https:\/\/doi.org\/10.1007\/bf02938395","journal-title":"Curr Cardiol Rep"},{"issue":"7347","key":"1_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317\u2013325. https:\/\/doi.org\/10.1038\/nature10146","journal-title":"Nature"},{"issue":"1","key":"1_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF (2012) Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 14(1):1\u201310. https:\/\/doi.org\/10.1007\/s11883-011-0219-7","journal-title":"Curr Atheroscler Rep"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.2538","volume":"17","author":"C Weber","year":"2011","unstructured":"Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410\u20131422","journal-title":"Nat Med"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2015.05.013","volume":"192","author":"R Ladeiras-Lopes","year":"2015","unstructured":"Ladeiras-Lopes R, Agewall S, Tawakol A et al (2015) Atherosclerosis: recent trials, new targets and future directions. Int J Cardiol 192:72\u201381","journal-title":"Int J Cardiol"},{"key":"1_CR52","doi-asserted-by":"crossref","unstructured":"Moss JWE, Williams JO, Ramji DP (2018) Nutraceuticals as therapeutic agents for atherosclerosis. Biochem Biophys Acta Mol Basis Dis 1864:1562\u20131572","DOI":"10.1016\/j.bbadis.2018.02.006"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","volume":"48","author":"LA Morehouse","year":"2007","unstructured":"Morehouse LA, Sugarman ED, Bourassa P-A et al (2007) Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48:1263\u20131272","journal-title":"J Lipid Res"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","volume":"20","author":"CW Rittershaus","year":"2000","unstructured":"Rittershaus CW, Miller DP, Thomas LJ et al (2000) Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20:2106\u20132112","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/35018119","volume":"406","author":"H Okamoto","year":"2000","unstructured":"Okamoto H, Yonemori F, Wakitani K et al (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203\u2013207","journal-title":"Nature"},{"issue":"9","key":"1_CR56","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1074\/jbc.273.9.5033","volume":"273","author":"M Sugano","year":"1998","unstructured":"Sugano M, Makino N, Sawada S et al (1998) Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273(9):5033\u20135036","journal-title":"J Biol Chem"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","volume":"23","author":"PJ Barter","year":"2003","unstructured":"Barter PJ, Chapman MJ, Hennekens CH et al (2003) Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160\u2013167","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1_CR58","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.1118","volume":"104","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ (2018) CETP-inhibition and HDL-cholesterol: a story of CV risk or CV benefit, or both. Clin Pharmacol Ther 104(2):297\u2013300","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1_CR59","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/imj.13451","volume":"47","author":"DJ Scherer","year":"2017","unstructured":"Scherer DJ, Nelson AJ, Psaltis PJ, Nicholls SJ (2017) Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Intern Med J 47(8):856\u2013865. https:\/\/doi.org\/10.1111\/imj.13451","journal-title":"Intern Med J"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2014.08.038","volume":"237","author":"TP Leren","year":"2014","unstructured":"Leren TP (2014) Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis 237:76\u201381","journal-title":"Atherosclerosis"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1194\/jlr.R026658","volume":"53","author":"G Lambert","year":"2012","unstructured":"Lambert G, Sjouke B, Choque B et al (2012) The PCSK9 decade. J Lipid Res 53:2515\u20132524","journal-title":"J Lipid Res"},{"issue":"21","key":"1_CR62","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/heartjnl-2016-310844","volume":"103","author":"S Hadjiphilippou","year":"2017","unstructured":"Hadjiphilippou S, Ray KK (2017) PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Heart 103(21):1670\u20131679. https:\/\/doi.org\/10.1136\/heartjnl-2016-310844","journal-title":"Heart"},{"issue":"16","key":"1_CR63","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright S, Kallend D et al (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 382(16):1507\u20131519","journal-title":"N Engl J Med"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","volume":"73","author":"L Jia","year":"2011","unstructured":"Jia L, Betters JL, Yu L (2011) Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol 73:239\u2013259. https:\/\/doi.org\/10.1146\/annurev-physiol-012110-142233","journal-title":"Annu Rev Physiol"},{"issue":"39","key":"1_CR65","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G et al (2016) ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(39):2999","journal-title":"Eur Heart J"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA et al (2013) AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 54:134\u2013151","journal-title":"J Lipid Res"},{"key":"1_CR67","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ et al (2019) Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 8:e011662","journal-title":"J Am Heart Assoc"},{"key":"1_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ et al (2018) Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypdercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 277:195\u2013203","journal-title":"Atherosclerosis"},{"issue":"6","key":"1_CR69","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK et al (2020) Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypdercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 27(6):593\u2013603","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"1_CR70","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"issue":"4","key":"1_CR71","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA et al (2013) Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61(4):404\u2013410","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"1_CR72","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381(26):2497\u20132505","journal-title":"N Engl J Med"},{"issue":"19","key":"1_CR73","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A et al (2020) Colchicine in patients with chronic coronary disease. N Engl J Med 383(19):1838\u20131847","journal-title":"N Engl J Med"},{"issue":"1","key":"1_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1074248413499972","volume":"19","author":"SM Nidorf","year":"2014","unstructured":"Nidorf SM, Eikelboom JW, Thompson PL (2014) Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Therapeut 19(1):45\u201352","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"1_CR75","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","volume":"269","author":"GJ Martinez","year":"2018","unstructured":"Martinez GJ, Celermajer DS, Patel S (2018) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 269:262\u2013271","journal-title":"Atherosclerosis"},{"issue":"25","key":"1_CR76","doi-asserted-by":"publisher","first-page":"37622","DOI":"10.18632\/oncotarget.9376","volume":"7","author":"S Xu","year":"2016","unstructured":"Xu S, Liu B, Yin M et al (2016) A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. Oncotarget 7(25):37622\u201337635","journal-title":"Oncotarget"},{"issue":"1","key":"1_CR77","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1038\/s41598-017-06803-x","volume":"7","author":"Y Xu","year":"2017","unstructured":"Xu Y, Liu P, Xu S et al (2017) Tannic acid as a plant-derived polyphenol exerts vasoprotection via enhancing KLF2 expression in endothelial cells. Sci Rep 7(1):6686","journal-title":"Sci Rep"},{"issue":"12","key":"1_CR78","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1017\/S000711451100256X","volume":"106","author":"GM Do","year":"2011","unstructured":"Do GM, Kwon EY, Ha TY et al (2011) Tannic acid is more effective than clofibrate for the elevation of hepatic beta-oxidation and the inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase and aortic lesion formation in apo E-deficient mice. Br J Nutr 106(12):1855\u20131863","journal-title":"Br J Nutr"},{"issue":"29","key":"1_CR79","doi-asserted-by":"publisher","first-page":"26714","DOI":"10.1074\/jbc.C500144200","volume":"280","author":"KM Parmar","year":"2005","unstructured":"Parmar KM, Nambudiri V, Dai G et al (2005) Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 280(29):26714\u201326719","journal-title":"J Biol Chem"},{"issue":"5","key":"1_CR80","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.104.525774","volume":"112","author":"S Sen-Banerjee","year":"2005","unstructured":"Sen-Banerjee S, Mir S, Lin Z et al (2005) Kruppel-like factor 2 as a novel mediator of stain effects in endothelial cells. Circulation 112(5):720\u2013726","journal-title":"Circulation"},{"key":"1_CR81","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","volume":"21","author":"M-R Taskinen","year":"2019","unstructured":"Taskinen M-R, Packard CJ, Boren J (2019) Emerging evidence that apoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep 21:27","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1_CR82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"I Blood","year":"2014","unstructured":"Blood I, Crosby J, Peloso GM et al (2014) Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have reduced risk of coronary heart disease. N Engl J Med 371(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"1","key":"1_CR83","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB Jorgensen","year":"2014","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG et al (2014) Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. N Engl J Med 371(1):32\u201341","journal-title":"N Engl J Med"},{"key":"1_CR84","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2017.05.003","volume":"30","author":"I Gouni-Berthold","year":"2017","unstructured":"Gouni-Berthold I (2017) The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atheroscler Suppl 30:19\u201327","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"1_CR85","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","volume":"12","author":"DJ Blom","year":"2018","unstructured":"Blom DJ, O\u2019Dea L, Digenio A et al (2018) Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study. J Clin Lipidol 12(5):1234\u20131243","journal-title":"J Clin Lipidol"},{"issue":"7","key":"1_CR86","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jacc.2009.02.084","volume":"54","author":"CJ Lavie","year":"2009","unstructured":"Lavie CJ, Milani RV, Mehra MR, Ventura HO (2009) Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 54(7):585\u2013594. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.084","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1_CR87","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","volume":"58","author":"D Mozaffarian","year":"2011","unstructured":"Mozaffarian D, Wu JHY (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58(20):2047\u20132067. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.063","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1_CR88","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","volume":"75","author":"PC Calder","year":"2013","unstructured":"Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 75(3):645\u2013662. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04374.x","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"1_CR89","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.2174\/092986708785132979","volume":"15","author":"PVA Babu","year":"2008","unstructured":"Babu PVA, Liu D (2008) Green tea catechins and cardiovascular health: an update. Curr Med Chem 15(18):1840\u20131850","journal-title":"Curr Med Chem"},{"issue":"4","key":"1_CR90","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1875-5364(13)60051-5","volume":"11","author":"P Bhardwaj","year":"2013","unstructured":"Bhardwaj P, Khanna D (2013) Green tea catechins: defensive role in cardiovascular disorders. Chin J Nat Med 11(4):345\u2013353. https:\/\/doi.org\/10.1016\/S1875-5364(13)60051-5","journal-title":"Chin J Nat Med"},{"issue":"5","key":"1_CR91","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1161\/ATVBAHA.117.309048","volume":"37","author":"DR Mangels","year":"2017","unstructured":"Mangels DR, Mohler ER (2017) Catechins as potential mediators of cardiovascular health. Arterioscler Thromb Vasc Biol 37(5):757\u2013763. https:\/\/doi.org\/10.1161\/ATVBAHA.117.309048","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1_CR92","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/FJC.0b013e3181c5e7fd","volume":"54","author":"M-I Covas","year":"2009","unstructured":"Covas M-I, Konstantinidou V, Fit\u00f3 M (2009) Olive oil and cardiovascular health. J Cardiovasc Pharmacol 54(6):477\u2013482. https:\/\/doi.org\/10.1097\/FJC.0b013e3181c5e7fd","journal-title":"J Cardiovasc Pharmacol"},{"issue":"25","key":"1_CR93","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas M-I, Corella D, Ar\u00f3s F, G\u00f3mez-Gracia E, Ruiz-Guti\u00e9rrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pint\u00f3 X, Basora J, Mu\u00f1oz MA, Sorl\u00ed JV, Mart\u00ednez JA, Fito M, Gea A, Hernan MA, Mart\u00ednez-Gonz\u00e1lez MA (2018) Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 378(25):e34\u2013e47. https:\/\/doi.org\/10.1056\/NEJMoa1800389","journal-title":"N Engl J Med"},{"issue":"13","key":"1_CR94","doi-asserted-by":"publisher","first-page":"e1800295","DOI":"10.1002\/mnfr.201800295","volume":"62","author":"A Luque-Sierra","year":"2018","unstructured":"Luque-Sierra A, Alvarez-Amor L, Kleemann R, Mart\u00edn F, Varela LM (2018) Extra-virgin olive oil with natural phenolic content exerts an anti-inflammatory effect in adipose tissue and attenuates the severity of atherosclerotic lesions in ldlr\u2212\/\u2212 Leiden mice. Mol Nutr Food Res 62(13):e1800295\u2013e1800328. https:\/\/doi.org\/10.1002\/mnfr.201800295","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"1_CR95","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792","journal-title":"N Engl J Med"},{"key":"1_CR96","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa750","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR (2020) Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J 41:3925\u20133932. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa750","journal-title":"Eur Heart J"},{"issue":"5","key":"1_CR97","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/ATVBAHA.111.237693","volume":"32","author":"GS Getz","year":"2012","unstructured":"Getz GS, Reardon CA (2012) Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 32(5):1104\u20131115","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1_CR98","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12944-016-0402-5","volume":"16","author":"YT Lee","year":"2017","unstructured":"Lee YT, Lin HY, Chan YWF et al (2017) Mouse models of atherosclerosis: a historical perspective and recent advances. Lipids Health Dis 16:12","journal-title":"Lipids Health Dis"},{"key":"1_CR99","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13353-013-0134-4","volume":"54","author":"R Mukhopadhyay","year":"2013","unstructured":"Mukhopadhyay R (2013) Mouse models of atherosclerosis: explaining critical roles of lipid metabolism and inflammation. J Appl Genet 54:185\u2013192","journal-title":"J Appl Genet"},{"key":"1_CR100","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/138945008783755575","volume":"9","author":"ME Rosenfeld","year":"2008","unstructured":"Rosenfeld ME, Averill MM, Bennett BJ et al (2008) Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets 9:210\u2013216","journal-title":"Curr Drug Targets"},{"issue":"2","key":"1_CR101","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1161\/ATVBAHA.119.313633","volume":"40","author":"J Cheng","year":"2020","unstructured":"Cheng J, Cheng A et al (2020) MicroRNA-144 silencing protects against atherosclerosis in male, but not female mice. Arterioscler Thromb Vasc Biol 40(2):412\u2013425","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1_CR102","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S0002-9440(10)63480-3","volume":"163","author":"M Zabalawi","year":"2003","unstructured":"Zabalawi M, Bhat S, Loughlin T et al (2003) Induction of fatal inflammation in LDL receptor and apoA-I double knockout mice fed dietary fat and cholesterol. Am J Pathol 163(6):1201\u20131213","journal-title":"Am J Pathol"},{"key":"1_CR103","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.artres.2017.08.002","volume":"20","author":"NA Mansukhani","year":"2018","unstructured":"Mansukhani NA, Wang Z, Shively VP et al (2018) Sex differences in the LDL receptor knockout mouse model of atherosclerosis. Artery Res 20:8\u201311","journal-title":"Artery Res"},{"issue":"10","key":"1_CR104","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1161\/01.ATV.0000235697.35431.05","volume":"26","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Wang X, Vales C et al (2006) FXR deficiency causes reduced atherosclerosis in Ldlr-\/- mice. Arterioscler Thromb Vasc Biol 26(10):2316\u20132321","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1_CR105","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/01.ATV.0000105054.43931.f0","volume":"24","author":"PA Vanderlaan","year":"2003","unstructured":"Vanderlaan PA, Reardon CA, Getz GS (2003) Site specificity of atherosclerosis. Arterioscler Thromb Vasc Biol 24(1):12\u201322","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1_CR106","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/genes11121427","volume":"11","author":"Y Kayashima","year":"2020","unstructured":"Kayashima Y, Maeda-Smithies N (2020) Atherosclerosis in different vascular locations unbiasedly approached with mouse genetics. Genes (Basel) 11(12):1427","journal-title":"Genes (Basel)"},{"issue":"8","key":"1_CR107","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Everett BM, Pradhan A et al (2018) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380(8):752\u2013762","journal-title":"N Engl J Med"},{"issue":"9313","key":"1_CR108","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hernan MA, Seeger JD et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359(9313):1173\u20131177","journal-title":"Lancet"},{"issue":"9","key":"1_CR109","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha R, Imamura F, Wyler Von Ballmoos M et al (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108(9):1362\u20131370","journal-title":"Am J Cardiol"},{"issue":"2","key":"1_CR110","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"SL Westlake","year":"2010","unstructured":"Westlake SL, Colebatch AN, Baird J et al (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49(2):295\u2013307","journal-title":"Rheumatology"}],"container-title":["Methods in Molecular Biology","Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1924-7_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T17:39:23Z","timestamp":1726767563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1924-7_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071619230","9781071619247"],"references-count":110,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1924-7_1","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-0716-1924-7","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"2 March 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}